Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Fibulin 3 (FBLN3)
EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5
- Product No.SEF422Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, urine and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range1.56-100ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.64ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 490
For more details, please contact local distributors! US$ 700 US$ 3150 US$ 5950 US$ 49000
Specificity
This assay has high sensitivity and excellent specificity for detection of Fibulin 3 (FBLN3).
No significant cross-reactivity or interference between Fibulin 3 (FBLN3) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Fibulin 3 (FBLN3) and the recovery rates were calculated by comparing the measured value to the expected amount of Fibulin 3 (FBLN3) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 90-101 | 97 |
EDTA plasma(n=5) | 92-101 | 97 |
heparin plasma(n=5) | 98-105 | 102 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibulin 3 (FBLN3) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibulin 3 (FBLN3) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fibulin 3 (FBLN3) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 86-93% | 93-104% | 80-91% | 92-105% |
EDTA plasma(n=5) | 86-103% | 83-94% | 95-105% | 90-97% |
heparin plasma(n=5) | 84-103% | 92-101% | 96-104% | 98-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
- Single-component Reagents of Assay Kit
- Lysis Buffer Specific for ELISA / CLIA
- Quality Control of Kit
- ELISA Kit Customized Service
- Disease Model Customized Service
- Serums Customized Service
- TGFB1 Activation Reagent
- Real Time PCR Experimental Service
- Streptavidin
- Fast blue Protein Stain solution
- Single-component Reagents of FLIA Kit
- Streptavidin-Agarose Beads
Magazine | Citations |
1 | Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma PubMed: PMC3761217 |
Anticancer Res. | YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. Pubmed: 24324091 |
Oncology Reports | Role of fibulin-3 in lung cancer: In vivo and in vitro analyses Spandidos-publications: Source |
Current Pulmonology Reports | Discovery of new biomarkers for malignant mesothelioma Springer:Source |
United States Patent Application 20140378336 | DIAGNOSIS OF CELL PROLIFERATIVE DISEASES Freepatentsonline:Source |
Thorax. | Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma Pubmed:Pmc4174124 |
Egyptian Journal of Chest Diseases and Tuberculosis | Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions Pubmed:23050525 |
Radiol Oncol | Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma PubMed: 26401134 |
British Journal of Cancer | Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis PubMed: 26263483 |
J Thorac Oncol. | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Pubmed:26903362 |
BMJ Open | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study pubmed:27884852 |
25 | HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients pubmed:26733616 |
BMJ Journals | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational … e013324.abstract |
Anticancer Res. | Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. pubmed:28314308 |
Dis Markers. | A Novel Panel of Serum Biomarkers for MPM Diagnosis. pubmed:28348450 |
The Knee | Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study pubmed:29195846 |
Disease markers | Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population pubmed:29200597 |
Molecular Medicine Reports | Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes Pubmed:29749501 |
Oncotarget | The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion Pubmed:30046386 |
Advances in Clinical and Experimental Medicine | Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with … 68362.pdf |
PLoS One | Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals Pubmed: 30946771 |
Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
RPF422Hu02 | Recombinant Fibulin 3 (FBLN3) | Positive Control; Immunogen; SDS-PAGE; WB. |
RPF422Hu01 | Recombinant Fibulin 3 (FBLN3) | Positive Control; Immunogen; SDS-PAGE; WB. |
PAF422Hu01 | Polyclonal Antibody to Fibulin 3 (FBLN3) | WB; IHC; ICC; IP. |
PAF422Hu02 | Polyclonal Antibody to Fibulin 3 (FBLN3) | WB; IHC; ICC; IP. |
LAF422Hu71 | Biotin-Linked Polyclonal Antibody to Fibulin 3 (FBLN3) | WB; IHC; ICC. |
MAF422Hu23 | Monoclonal Antibody to Fibulin 3 (FBLN3) | WB; IHC; ICC; IP. |
MAF422Hu24 | Monoclonal Antibody to Fibulin 3 (FBLN3) | WB; IHC; ICC; IP. |
MAF422Hu22 | Monoclonal Antibody to Fibulin 3 (FBLN3) | WB |
MAF422Hu25 | Monoclonal Antibody to Fibulin 3 (FBLN3) | WB |
MAF422Hu21 | Monoclonal Antibody to Fibulin 3 (FBLN3) | WB |
SEF422Hu | ELISA Kit for Fibulin 3 (FBLN3) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCF422Hu | CLIA Kit for Fibulin 3 (FBLN3) | Chemiluminescent immunoassay for Antigen Detection. |
LMF422Hu | Multiplex Assay Kit for Fibulin 3 (FBLN3) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |